Jagsonpal Pharmaceuticals Limited — Others, 21-02-2025: Action(s) taken or orders passed

Jagsonpal Pharmaceuticals Limited has received a warning letter from the USFDA concerning CGMP deviations and registration violations observed during an inspection of its contract manufacturing facility. The company estimates that this could impact sales by approximately ₹3.5 Cr (1.46% of current fiscal year sales). As the company relies heavily on one OTC API supplied to the US and has no product pipeline, this development raises potential risks regarding future revenue and operational stability. Investors may perceive this as a negative outlook, given the implications for growth and compliance.